Declan Doogan Sells 121,942 Shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stock

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Declan Doogan sold 121,942 shares of the firm’s stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $26.78, for a total transaction of $3,265,606.76. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Declan Doogan also recently made the following trade(s):

  • On Wednesday, January 10th, Declan Doogan sold 40,362 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $27.69, for a total transaction of $1,117,623.78.

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) opened at $26.44 on Friday. The stock has a market cap of $1,100.00 and a P/E ratio of -5.07. Biohaven Pharmaceutical Holding Co Ltd has a 52 week low of $17.00 and a 52 week high of $39.51.

Several brokerages have recently issued reports on BHVN. Piper Jaffray Companies set a $48.00 price objective on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Monday, December 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Biohaven Pharmaceutical in a research note on Wednesday, November 15th. BidaskClub raised shares of Biohaven Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 28th. Morgan Stanley reaffirmed an “overweight” rating and issued a $38.00 price objective (down previously from $47.00) on shares of Biohaven Pharmaceutical in a research note on Tuesday, October 3rd. Finally, William Blair reaffirmed an “outperform” rating on shares of Biohaven Pharmaceutical in a research note on Tuesday, October 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $36.14.

Several institutional investors and hedge funds have recently made changes to their positions in BHVN. Deschutes Portfolio Strategy LLC acquired a new position in shares of Biohaven Pharmaceutical in the 3rd quarter worth approximately $374,000. Strs Ohio purchased a new position in shares of Biohaven Pharmaceutical in the third quarter worth approximately $680,000. Nationwide Fund Advisors purchased a new position in shares of Biohaven Pharmaceutical in the third quarter worth approximately $214,000. Emerald Advisers Inc. PA purchased a new position in shares of Biohaven Pharmaceutical in the third quarter worth approximately $9,096,000. Finally, Emerald Mutual Fund Advisers Trust purchased a new position in shares of Biohaven Pharmaceutical in the third quarter worth approximately $7,483,000. 47.76% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Declan Doogan Sells 121,942 Shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stock” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/14/declan-doogan-sells-121942-shares-of-biohaven-pharmaceutical-holding-co-ltd-bhvn-stock.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply